Eli Lilly (LLY) is planning to appeal against the UK's National Institute for Health and Care Excellence's, or NICE's, suggestion not to reimburse the cost of Alzheimer's drug Kisunla, Reuters reported Thursday, citing the company.
According to the report, the drugmaker considers the regulator's recommendation to be unreasonable based on the evidence submitted by the company, clinical experts and patient groups.
Neither Lilly nor NICE immediately responded to MT Newswires' request for comment.
Lilly's shares added 0.6% in recent Friday premarket activity.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.